搜尋結果
The Novavax COVID‑19 vaccine is indicated for active immunization to prevent COVID‑19 caused by SARS-CoV-2. [4] Efficacy. A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. [30] .
- AU: B1
- Intramuscular
- Covovax, Nuvaxovid
- SARS-CoV-2
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases.
- 1987; 36 years ago
- Gaithersburg, Maryland, U.S.
- 1,541 (2022)
- US$1.982 billion (2022)
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, is a subunit COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations. Full (4) Australia Canada Japan South Korea
On 9 September, the second batch of the Pfizer–BioNTech COVID-19 vaccine, with 910,000 doses, arrived in Taiwan. Combined with the first batch, the 1.8 million dose of Pfizer-BioNTech COVID-19 vaccine will be used for the youth vaccination program, ranging from age 12 to 22.
CoronaVac, also known as the Sinovac COVID-19 vaccine, is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was phase III clinically trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine ...
Matrix-M is a vaccine adjuvant, a substance that is added to various vaccines to stimulate the immune response. [1] [2] [3] It was patented in 2020 by Novavax [4] and is composed of nanoparticles from saponins extracted from Quillaja saponaria (soapbark) trees, cholesterol, and phospholipids.
e. The MVC COVID-19 vaccine ( Chinese: 高端新冠肺炎疫苗; pinyin: Gāoduān xīnguàn fèiyán yìmiáo; Wade–Giles: Kaotuan hsinkuan feiyen imiao ), designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine, is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company ...
